GlobeNewswire by notified

PUBLICATION OF A TRANSPARENCY NOTIFICATION

Share

Publication on November 29, 2023 at 18:30 CET after market closing
Regulated information
EVS Broadcast Equipment S.A.: Euronext Brussels (EVS.BR), Bloomberg (EVS BB), Reuters (EVSB.BR)

PUBLICATION OF A TRANSPARENCY NOTIFICATION

(Article 14, first paragraph, of the Law of 2 May 2007 on disclosure of major holdings)

On November 27, 2023, EVS Broadcast Equipment has received a transparency notification indicating that Otus Capital Management Limited now holds 4.99% of the voting rights of the company. Otus Capital Management Limited has therefore crossed down the threshold of 5%.

The notification, dated November 27, 2023, contains the following information:

  • Reason for the notification: acquisition or disposal of voting securities or voting rights
  • Notification by: A parent undertaking or a controlling person
  • Persons subject to the notification requirement: Otus Capital Management Limited, 29 Queen Anne’s Gate, London SW1H 9BU, UK; Andrew Gibbs
  • Transaction date: November 24, 2023
  • Threshold that is crossed (in %): 5%
  • Denominator: 14,327,024
A) Voting rightsPrevious notificationAfter the transaction
# voting rights# voting rights% voting rights
Holders of voting rightsLinked to securitiesNot linked to the securitiesLinked to securitiesNot linked to the securities
Andrew Gibbs000,00%
Otus Capital Management Limited820.529714.7924.99%
TOTAL714.79204.99%0,00%
B) Equivalent financial instrumentsAfter the transaction
Holders of equivalent financial instrumentsType of financial
Instruments
Expiration
date
Exercise period or date# of voting rights that may be acquired if the instrument is exercised% of voting rightsSettlement
TOTAL00,00%
TOTAL (A & B)# voting rights% of voting rights
TOTAL (A & B)714.7924.99%
  • Full chain of controlled undertakings through which the holding is effectively held: Otus Capital Management Ltd acts as the investment manager (with control of voting rights) for: The Maga Micro Cap Fund, Regents of the University of Michigan and LGT Select Equity Global-Pool Otus, that hold the shares reported here. Otus Capital Management Ltd is 30% owned by Canepa-OCM Holdings Limited & is 70% owned by Andrew Gibbs.
  • Additional information: Otus Capital Management Ltd is the discretionary investment manager and exercises the voting rights at its discretion in the absence of specific instructions.

This press release and the notification are available on the EVS website (www.evs.com).

EVS values transparency and compliance with regulatory obligations and is committed to keeping its shareholders and stakeholders informed about developments that may impact the ownership structure. EVS remains focused on its strategic objectives and is confident in its ability to deliver value to its shareholders.

Shareholders must declare their ownership in EVS shares as soon as their shareholding passes over/under the 3% threshold (required by Company Statutes) and any multiple of 5% thresholds (required by Belgian Law). Notifications of important shareholdings to be made according to the Law of May 2, 2007 and the EVS's bylaws, should be sent to the company (by email corpcom@evs.com or fax +32 4 361 7089) and to the FSMA. The current number of shares (denominator) to be taken into account is 14,327,024 shares.

For more information, please contact:



Veerle De Wit, CFO*
EVS Broadcast Equipment S.A., Liege Science Park, 13 rue Bois Saint-Jean, B-4102 Seraing, Belgium
Tel: +32 4 361 70 04.  E-Mail:corpcom@evs.com; www.evs.com
* representing a SRL


Forward Looking Statements
This press release contains forward-looking statements with respect to the business, financial condition, and results of operations of EVS and its affiliates. These statements are based on the current expectations or beliefs ’f EVS's management and are subject to a number of risks and uncertainties that could cause actual results or performance of the Company to differ materially from those contemplated in such forward-looking statements. These risks and uncertainties relate to changes in technology and market requirements, the company’s concentration on one industry, decline in demand for the company’s products and those of its affiliates, inability to timely develop and introduce new technologies, products and applications, and loss of market share and pressure on pricing resulting from competition which could cause the actual results or performance of the company to differ materially from those contemplated in such forward-looking statements. EVS undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

About EVS
EVS is globally recognized as the leader in live video technology for broadcast and new media productions. Our passion and purpose are to help our clients craft immersive stories that trigger the best return on emotion. Through a wide range of products and solutions, we deliver the most gripping live sports images, buzzing entertainment shows and breaking news content to billions of viewers every day – and in real-time.
The company is headquartered in Belgium with offices in Europe, the Middle East, Asia and North America, and provides sales and technical support to more than 100 countries. EVS is a public company traded on Euronext Brussels: EVS, ISIN: BE0003820371.
For more information, please visit www.evs.com.

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Press Release: Phase 2 results demonstrate rilzabrutinib rapidly reduced itch severity and significantly improved disease activity in adults with chronic spontaneous urticaria24.2.2024 15:51:43 CET | Press release

Phase 2 results demonstrate rilzabrutinib rapidly reduced itch severity and significantly improved disease activity in adults with chronic spontaneous urticaria Late-breaking data at 2024 AAAAI showed rilzabrutinib, an oral BTK inhibitor, significantly reduced weekly itch severity score (ISS7) as early as the first week of treatment in adults with moderate to severe CSUData form the basis for the Phase 3 CSU and prurigo nodularis programs to start in 2024Pivotal Phase 3 readout in immune thrombocytopenia and Phase 2 readouts in asthma, IgG4-related disease and warm autoimmune hemolytic anemia expected in 2024Rilzabrutinib is one of 12 potential blockbusters in Sanofi’s leading immunology pipeline Paris, February 24, 2024. Positive results from the Phase 2 study RILECSU showed that rilzabrutinib significantly improved itch, hives and urticaria in adults with moderate-to-severe chronic spontaneous urticaria (CSU), whose symptoms are not adequately controlled by H1 antihistamines. These r

Application to delist from Nasdaq First North Growth Market Denmark submitted24.2.2024 14:17:57 CET | Press release

Copenhagen, Feb. 24, 2024 (GLOBE NEWSWIRE) -- Announcement no. 3-2024 Hypefactors has submitted an official application to delist from Nasdaq First North Growth Market Denmark. A decision backed by 98,42% of the share capital represented at the Extraordinary General Meeting held on 23. February 2024 Delisting requires the final approval from Nasdaq. The details of​ the delisting ​procedure and ​consequenses for shareholders is stated in the company announcement 01-2024. ---- About Hypefactors A/S Hypefactors is an AI based reputation and corporate trust technology company, providing a tech platform to support better media intelligence and reputation/trust management. Hypefactors combine data, analytics, technology, and tools to provide a unified and easy-to-use experience. With all the tools to automate and ease the work, and all the facts to document the results. In addition to media monitoring across the different media channels, the platform provides access to several facts, incl. a

798 Launches Folk Culture Sector of Square Art Festival, 110,000+ Visitors Reached During the Chinese New Year Vacation24.2.2024 03:00:00 CET | Press release

BEIJING, Feb. 24, 2024 (GLOBE NEWSWIRE) -- 798 Art District announces today that the Folk Culture Sector of the 798 Square Art Festival will launch on February 24, 2024, at the CONCERTED SQUARE of 798 Art District in Beijing. This sector aims to bridge contemporary art with urban and rural folk culture. Visiting 798 during the Lantern Festival, you can experience the power of contemporary art intertwined with traditional folk customs and enjoy the familiar yet strange world of Chinese local culture. Event Poster February 24 is the Lantern Festival in China, and it marks the end of the Chinese New Year festivities. The New Year vacation in 798 was full of lively atmosphere. Throughout the Spring Festival, 15 exhibitions were ongoing in 798, including the Joy Art Museum's "Joy in the Year of the Dragon", IOMA Art Center's "Dragon Roaming the World and Prospering", MOCUBE's "Upon Arrival of Dragon", and Le Rime Gallery's "Jia Chen Mountain Chronicle". Based on statistics, there were over

Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®24.2.2024 02:15:00 CET | Press release

SIMLANDI is the first citrate-free, high-concentration biosimilar to be designated interchangeable to Humira in the U.S. SIMLANDI is the first biosimilar approval under the strategic partnership between Alvotech and Teva in the U.S. market SIMLANDI will qualify for interchangeable exclusivity in the U.S. for some concentration strengths Alvotech (NASDAQ: ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has approved SIMLANDI (adalimumab-ryvk) injection, as an interchangeable biosimilar to Humira, for the treatment of adult rheumatoid arthritis, juvenile idiopathic arthritis, adult psoriatic arthritis, adul Alvotech (NASDAQ: ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has approved SIMLANDI (adalimumab-ryvk) injection, as an interchan

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons23.2.2024 23:50:47 CET | Press release

Company Announcement COPENHAGEN, Denmark; February 23, 2024 –Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons. The company’s managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behalf to publish trading in Genmab shares by the company’s managerial employees and their closely associated persons. Please find below a statement of such trading in shares issued by Genmab A/S 1.Details of the person discharging managerial responsibilities / person closely associateda)NameJan G. J. van de Winkel2.Reason for the notificationa)Position/statusPresident & Chief Executive Officerb)Initial notification/AmendmentInitial notification3.Details of the issuer, emission allowance market participant, auction platform,

HiddenA line styled icon from Orion Icon Library.Eye